KL-6 was first suggested as a serum biomarker for lung, breast, and pancreatic cancer, but showed lower diagnostic accuracy than other tumor markers, such as carcinoembryonic antigen (CEA), a reliable predictor of treatment response in non-small-cell lung cancer [3]. This evidence concerns the gene CEACAM5 and pancreatic neoplasm.